At high temperatures and low pressures, the outgassing from Silicone rubber  is inevitable if the hose is not set to a curing process.

The post-curing process (or post-vulcanization) avoids outgassing: the volatile particles present in the hose are extracted and removed from the cross-linked silicone rubber  by diffusion and evaporation,  at a temperature higher  than the service temperature.
In presence of high temperatures with poor ventilation, a Silicone rubber hose not subjected to this important process sees a drop in performances and mechanical properties: elongation, low resistance, strength reduction, delamination, swelling, sticky surface, contamination of the substances transferred.

....An innovative alternative to Silicone rubber is IPL’s TPE range:

Pharmapress, Pharmapress HT, Pharmasteel, Pharmasteel press HT, Plutone PF: ideal for transfering food, pharmaceutical and cosmetic substances such as abrasive powderscosmetic, health care, creams, soaps, aromas, pigments, wines, fruit juices, vinegar, spirits with max. 50% alcohol content, milky and dairy products etc. according to all the current Regulation: EC n° 2023/2006 (GMP = Good Manufacturing Practices) - EC n° 10/2011 Regulation -  FDA (Food and Drug Administration) title 21 CFR 177.2600 Regulation -  USP (United States Pharmacopeia) CLASS VI.

IPL’s TPE (ThermoPlastic Elastomers) ensures a utmost purity requested in food,pharceutical and cosmetic industries. This type of material does not need any post curing process, which, if not carried out properly, is the main responsible for the potential leaching of substances into the medium. 

Advantages in using PTE products:

  • minimum risk rate of contamination of the substances transferred
  • really good mechanical properties and features
  • no swelling
  • no delamination
  • no sticky surface deposits
  • IPL’s curing-free compounds allow to save costs and energies during the productionprocess, reducing CO2 emissions and safeguarding the environment.
Attachment Size
Food Compliance UE Rev 00 141211.pdf 167.95 KB
Compliance Prospectus FDA- USP- Eu Ph Rev 00 220312.pdf 105.59 KB